Still, Judge Rosenberg found that the plaintiffs had not succeeded in establishing a sufficient threshold beyond which the presence of NDMA would cause a person to develop cancer. The dismissal of thousands of Zantac lawsuits comes despite the court itself acknowledging in its order that the private testing company Valisure had discovered that, while “the FDA’s self-determined daily limit for NDMA in a drug is 96 nanograms, or ng…Valisure’s tests found NDMA in ranitidine in excess of 3,000,000 ng.” The determination came after Judge Rosenberg, earlier in the same order, granted the defendants’ requests to exclude essential aspects of the plaintiffs’ expert testimony. ![]() In the December 6 omnibus order, US District Judge Robin Rosenberg found that the plaintiffs had failed to provide sufficient proof that Zantac caused the plaintiffs’ cancer. Representatives of the defendant drug companies-which included GlaxoSmithKline (GSK), Boehringer, Pfizer and Sanofi-expressed satisfaction with the judge’s ruling, though some noted that the companies still face tens of thousands of Zantac cases in state courts across the US. The plaintiff lawyers further expressed great confidence that the ruling would be overturned on appeal. “We are extremely surprised by this miscarriage of justice,” lawyers for the plaintiffs said in a joint statement quoted by Reuters. Thousands sued the drug makers, alleging that the drugs had given them or their loved one cancer and seeking to hold the defendant drug companies responsible.īy the time of the judge’s ruling, the Zantac MDL included more than 2,000 active cases, all of them dismissed in a single day by a single order. Given the popularity and longevity of Zantac and, later, generic ranitidine, millions of individuals were potentially impacted. The recall followed the United States Food and Drug Administration’s (FDA) April 1 announcement that the agency was requesting not only a recall but a complete and permanent withdrawal from the market. The Zantac MDL arose out of the April 2020 recall of all ranitidine-containing drugs after the carcinogen NDMA was detected in the one-time blockbuster medication. ![]() ![]() Thousands of plaintiffs alleging that they had developed cancer because of tainted Zantac and generic ranitidine saw their cases dismissed on Tuesday, December 6, when the judge overseeing multidistrict litigation (MDL) over the recalled heartburn drug granted the defendants’ motion for summary judgment. Zantac Lawsuit Update: Zantac MDL Judge Dismisses Thousands of Cancer Lawsuits
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |